09:47 AM EST - Trillium Therapeutics Inc. : Provided an update today on its ongoing phase 1b dose optimization study of TTI-621 in patients with relapsed and/or refractory cutaneous T-cell lymphoma (CTCL). TTI-621 is an innate immune checkpoint inhibitor targeting CD47, a "don’t-eat-me" signal that cancer cells use to evade destruction by the immune system. Trillium Therapeutics Inc.
shares T.TRIL are trading down $1.41 at $8.07.
